Study record · Tesamorelin
Tesamorelin and neurocognitive impairment in people with HIV and abdominal obesity
Within-group cognitive score improved numerically with tesamorelin, but the between-group difference was not significant (P=0.673); waist circumference.
Key result
Within-group cognitive score improved numerically with tesamorelin, but the between-group difference was not significant (P=0.673); waist circumference declined more with tesamorelin.
Study details
Study designRandomized open-label Phase II trial
PhasePhase II
PopulationVirally suppressed people with HIV, abdominal obesity and neurocognitive impairment
Sample size73
RouteSubcutaneous
Regimen / exposureTesamorelin 2 mg once daily
Duration6 months
ComparatorStandard of care
Primary endpoint / questionChange in neurocognitive performance
Safety resultNo major new safety conclusion can be drawn from the small open-label study.
Key limitationsUnderpowered, no placebo arm, short duration; does not demonstrate cognitive efficacy.
Registry / identifierPMID 39813152